Overview

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

Status:
Not yet recruiting

Trial end date:
2029-07-31

Target enrollment:

Participant gender:

Summary

REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.

Phase:

Phase 3

Details

Lead Sponsor:

Johns Hopkins University

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)